NASDAQ · BLTE
Belite Bio financials
$166.66+0.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$84.2M | -$40.0M | -$31.7M | -$12.8M |
| Net income | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| Net margin | — | — | — | — |
| Diluted EPS | $-2.31 | $-1.18 | $-1.19 | $-0.63 |
| EBITDA | -$84.0M | -$39.8M | -$31.5M | -$12.8M |
| Operating cash flow | -$37.0M | -$29.2M | -$29.8M | -$11.5M |
| Free cash flow | -$37.2M | -$29.4M | -$29.9M | -$11.9M |
| Diluted shares | 33.5M | 30.5M | 26.6M | 20.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $352.9M | $31.7M | $88.2M | $42.1M |
| Short-term investments | $139.5M | $113.5M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $780.6M | $152.1M | $94.6M | $44.3M |
| Total liabilities | $10.1M | $6.3M | $4.2M | $2.8M |
| Shareholders' equity | $770.5M | $145.8M | $90.4M | $41.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology